N/A N=998 Multicenter, Non-interventional Study, Describing Patients With Inherited Retinal Disease (IRD) in France
Inherited Retinal Disease
Primary: Proportion of Patients by Type of IRD — 720; 174; 30; 58 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa · X-linked Genetic Diseases
Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30
Phase 2 N=8 A Study in Subjects With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 2 N=45 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
Phase 2 N=15 Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Leber Congenital Amaurosis
Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants
Phase 2 N=27 Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
X-linked Retinoschisis
Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants
Phase 1 N=6 Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)
Retinal Disease · Retinitis Pigmentosa
Primary: Systemic and Ocular Safety — 0; 0; 1; 0 Participants
Phase 2 N=12 Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Leber Congenital Amaurosis
Primary: Number of Participants Experiencing Ocular or Non-ocular Adverse Events — 6; 6 participants
Phase 2 N=11 Gene Therapy for Achromatopsia (CNGA3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
Phase 2 N=23 Gene Therapy for Achromatopsia (CNGB3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
N/A N=40 Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Retinitis Pigmentosa · AMD
Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05
Phase 2 N=18 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
X-Linked Retinitis Pigmentosa
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=12 Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Retinoschisis · X-Linked
Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events
Phase 2 N=14 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Advanced Retinitis Pigmentosa
Primary: Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597 — 0; 0; 0; 0 participants
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
N/A N=110 Infrared Choroidal Reflectance Camera for the Detection of Childhood Cataract
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes
Phase 2 N=90 Trial of Oral Valproic Acid for Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Mean Change in Visual Field Area From Baseline to 52 Weeks--III4e Isopter — -122.9; -112.0; -293.7; -237.1 Visual field area (degrees squared) — p=0.035
N/A N=219 Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Leber's Hereditary Optic Neuropathy (LHON)
Primary: In Eyes With VA Assessment Made ≤1 Year After Onset of Symptoms: Proportion of Eyes With Clinically Relevant Recovery (CRR) of VA (Measured by Change in ETDRS Letters)…
Phase 2 N=83 Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Best Corrected Visual Acuity (BCVA) — 3.9; 1.3; 2.6 Letters correct — p=0.582
Phase 2 N=16 FRDA Investigator Initiated Study (IIS) With Elamipretide
Friedreich Ataxia
Primary: Change in High Contrast Visual Acuity — 5.5; 0 Number of Letters Read on a Vision Board
N/A N=21 Visual Activity Evoked by Infrared in Humans After Dark Adaptation
Age Related Macular Degeneration · Retinitis Pigmentosa · Congenital Stationary Night Blindness
Primary: Visual Perception to Infrared: Mean Minimal Intensity (uW) at Which Participants Could See IR Between 900 - 1400 nm. — 0.671770454; 0.809204; 0.205456012; 0.222247 uW…
N/A N=26 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05
Phase 2 N=146 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB
N/A N=251 A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Stargardt Disease
Primary: Yearly Progression Rate of Atrophic Lesions Using Fundus Autofluorescence (FAF) Images — 0.35; 0.64 mm^2/year
Phase 2 N=28 Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
Retinitis Pigmentosa (RP)
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 25; 21; 1 Participants
Phase 2 N=18 Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)
Phase 2 N=6 Choroideremia Gene Therapy Clinical Trial
Choroideremia
Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 2 N=131 Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
Age Related Macular Degeneration
Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…